PTGS1 and Parkinson disease: In vitro, in a model of Parkinson’s disease, THCA-A inhibits COX1 and COX2 and reduces the viability of various lines of cancerous cells as it significantly enriches the altered morphology of neurites, in a model of Parkinson’s disease [67].